profit from every €100 of sales.
€0€100
Qiagen
€45.37+0.30% today
+12.1% since Dec 18, 25
1-year low €28.111-year high €46.43
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay €24.46 for every €1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Qiagen sold, what it kept, and what it did with the cash.
Sales went from $2.14 billion in 2022 to $2.09 billion in 2025, with $425 million of profit last year.
SalesProfit
Qiagen handed back 12% of the cash it generated last year.
$54M
Free cash flow 2025$447M
Bought back its own shares–
Paid as dividends$54M
Cash vs. debt$839M vs. $1.8B
Qiagen vs. similar companies
Qiagen grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| Qiagen | 24.5× · Fair price | ||
 Thermo Fisher Scientific | 39.7× · Expensive | ||
 Danaher | 45.8× · Expensive | ||
 WuXi AppTec | 26.5× · Fair price | ||
 Lonza Group | No profit yet |
AI analysis
An AI analyst reads Qiagen's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 2,142 | 1,965 | 1,978 | 2,090 | |
| 1,385 | 1,234 | 967 | 1,299 | |
| 576 | 445 | 200 | 520 | |
| 779 | 689 | 368 | 717 | |
| 423 | 341 | 84 | 425 | |
| 1.99 | 1.65 | 0.40 | 2.04 | |
| 64.7% | 62.8% | 48.9% | 62.2% | |
| 26.9% | 22.7% | 10.1% | 24.9% | |
| 19.8% | 17.4% | 4.2% | 20.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 6,288 | 6,115 | 5,690 | 6,281 |
| Cash | 731 | 668 | 664 | 839 |
| Total debt | 1,884 | 1,532 | 1,513 | 1,812 |
| Total liabilities | 2,821 | 2,307 | 2,122 | 2,503 |
| 3,467 | 3,808 | 3,567 | 3,778 | |
| 213 | 207 | 208 | 208 | |
| 7.5% | 6.3% | 2.3% | 6.6% | |
| 12.2% | 9.0% | 2.3% | 11.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 715 | 459 | 674 | 654 | |
| 149 | 163 | 171 | 207 | |
| 566 | 297 | 502 | 447 | |
| Dividends paid | – | 0 | 0 | 54 |
| 0 | 0 | 292 | – | |
| 50 | 47 | 44 | 50 |
Valuation
- 24.5×
- –
- 29.52
- 2.8×
- 5.0×
- 23.2×
- 15.8×
- 4.3%
- 4.1%
- 0.5%
Profitability
- 62.2%
- 24.9%
- 20.3%
- –
- 6.6%
- 5.7%
- –
- –
- –
- –
Growth
- −0.8%
- +0.8%
- –
- –
- +0.3%
Financial health
- 1.4×
- 0.48
- –
- 15.7×
- 3.90
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 45%of 959
Top 14%of 888
Top 46%of 599
Bottom 16%of 889
Top 27%of 987
0.5%of the share price, paid each year
On $1,000 invested$5a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
12.8% of its profit
Room to growStretchedMore than it earns: 12.1%
News
Brookfield, QIA to invest $3.4B in UK data center project with DraxSeeking Alpha · Nov 3, 2026Qiagen agrees to €46.50/share all-cash takeover offer from EQTSeeking Alpha · Oct 22, 2026Qiagen reports preliminary Q3 resultsSeeking Alpha · Oct 22, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
56No pass
Benjamin Graham
59No pass
Philip Fisher
56No pass
Peter Lynch
19No pass
Joel Greenblatt
20No pass
Charlie Munger
53No pass
Terry Smith
49No pass
Questions about Qiagen
Is Qiagen a good stock to buy?
A strong, very profitable business at a fair price. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Qiagen AI analysis
What does Qiagen do?
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. It is in Diagnostics & Research, based in Venlo, Netherlands, with 5,500 employees.
Does Qiagen pay a dividend?
Yes. At today's price the dividend is 0.5% a year, about 13% of its yearly profit. In 2025 it paid out €54.2 million in dividends.
Is Qiagen stock halal?
Yes. Qiagen passes our halal screen: its business is permitted and its debt is 17% of its market value, under the 30% limit. How we check
Who are Qiagen's competitors?
The largest listed companies in the same industry are Thermo Fisher Scientific, Danaher, WuXi AppTec and Lonza Group. The peers table on this page compares their profit, growth and price with Qiagen's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.